Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
4.
J Exp Bot ; 58(2): 279-89, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-16990373

RESUMO

Regionally distinct elongation responses to water stress in the maize primary root tip have been observed in the past. A genetic basis for such differential responses has been demonstrated. Normalized bar-coded cDNA libraries were generated for four regions of the root tip, 0-3 mm (R1), 3-7 mm (R2), 7-12 mm (R3), and 12-20 mm (R4) from the root apex, and transcript profiles for these regions were sampled. This permitted a correlation between transcript nature and regional location for 15 726 expressed sequence tags (ESTs) that, in approximately equal numbers, derived from three conditions of the root: water stress (water potential: -1.6 MPa) for 5 h and for 48 h, respectively, and well watered (5 h and 48 h combined). These normalized cDNA libraries provided 6553 unigenes. An analysis of the regional representation of transcripts showed that populations were largely unaffected by water stress in R1, correlating with the maintenance of elongation rates under water stress known for R1. In contrast, transcript profiles in regions 2 and 3 diverged in well-watered and water-stressed roots. In R1, transcripts for translation and cell cycle control were prevalent. R2 was characterized by transcripts for cell wall biogenesis and cytoskeleton formation. R3 and R4 shared prevalent groups of transcripts responsible for defence mechanisms, ion transport, and biogenesis of secondary metabolites. Transcripts which were followed for 1, 6, and 48 h of water stress showed distinct region-specific changes in absolute expression and changes in regulated functions.


Assuntos
Regulação da Expressão Gênica de Plantas , Genes de Plantas/genética , Raízes de Plantas/genética , Raízes de Plantas/metabolismo , Transcrição Gênica , Água/metabolismo , Zea mays/genética , Etiquetas de Sequências Expressas , Perfilação da Expressão Gênica , Zea mays/metabolismo
5.
Gastroenterol Clin Biol ; 25(5): 549-51, 2001 May.
Artigo em Francês | MEDLINE | ID: mdl-11521110

RESUMO

Portal vein thrombosis, except in hepatocellular carcinoma and severe cirrhosis, is due to one or several prothrombotic disorders with or without a local precipitating factor. We report a case of a portal and splenic vein thrombosis, without cavernoma and varices which occurred in a 72-year-old man with abdominal pain and weakness. Three prothrombotic states including latent myeloproliferative disorder, antiphospholipid syndrome, and factor II G202101 mutation, were observed. Anticoagulant treatment resulted in complete repermeation of the portal and splenic veins without a hemorrhagic event. This illustrates that several prothrombotic states may occur in a single patient with portal vein thrombosis. Early anticoagulant therapy, in recent portal vein thrombosis, can result in repermeation.


Assuntos
Anticoagulantes/uso terapêutico , Síndrome Antifosfolipídica/complicações , Transtornos Mieloproliferativos/complicações , Veia Porta , Protrombina/genética , Trombose Venosa/etiologia , Idoso , Humanos , Masculino , Mutação , Veia Esplênica , Tomografia Computadorizada por Raios X , Trombose Venosa/tratamento farmacológico , Trombose Venosa/genética
6.
J Exp Bot ; 51(350): 1575-84, 2000 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11006308

RESUMO

To examine whether the reduced shoot growth of abscisic acid (ABA)-deficient mutants of tomato is independent of effects on plant water balance, flacca and notabilis were grown under controlled-humidity conditions so that their leaf water potentials were equal to or higher than those of well-watered wild-type plants throughout development. Most parameters of shoot growth remained markedly impaired and root growth was also greatly reduced. Additional experiments with flacca showed that shoot growth substantially recovered when wild-type levels of ABA were restored by treatment with exogenous ABA, even though improvement in leaf water potential was prevented. The ability of applied ABA to increase growth was greatest for leaf expansion, which was restored by 75%. The ethylene evolution rate of growing leaves was doubled in flacca compared to the wild type and treatment with silver thiosulphate to inhibit ethylene action partially restored shoot growth. The results demonstrate that normal levels of endogenous ABA are required to maintain shoot development, particularly leaf expansion, in well-watered tomato plants, independently of effects on plant water balance. The impairment of shoot growth caused by ABA deficiency is at least partly attributable to ethylene.


Assuntos
Ácido Abscísico/fisiologia , Etilenos/metabolismo , Brotos de Planta/crescimento & desenvolvimento , Solanum lycopersicum/crescimento & desenvolvimento , Água
7.
Gastroenterol Clin Biol ; 24(6-7): 671-4, 2000.
Artigo em Francês | MEDLINE | ID: mdl-10962392

RESUMO

Reactivation of chronic infection is a serious complication during and especially after the withdrawal of cancer chemotherapy in hepatitis B virus carriers. Mortality is high, ranging from 4 to 20%. We report two cases of severe reactivation, after withdrawal of chemotherapy for chronic lymphocytic leukemia in one case and for a bladder tumor in the other. Recovery occurred with lamivudine therapy. Morbidity and mortality are common in these cases, especially when intensive chemotherapy and/or chronic hepatitis and/or precore mutants viruses are involved. Although lamivudine seems to be effective in these cases, prophylactic use has not been clearly defined and must be evaluated.


Assuntos
Antineoplásicos/administração & dosagem , Antivirais/uso terapêutico , Hepatite B/tratamento farmacológico , Lamivudina/uso terapêutico , Idoso , Feminino , Hepatite B/complicações , Humanos , Leucemia Linfocítica Crônica de Células B/complicações , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Masculino , Recidiva , Neoplasias da Bexiga Urinária/complicações , Neoplasias da Bexiga Urinária/tratamento farmacológico
8.
Plant Physiol ; 122(3): 967-76, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10712561

RESUMO

Previous work showed that primary root elongation in maize (Zea mays L.) seedlings at low water potentials (psi(w)) requires the accumulation of abscisic acid (ABA) (R.E. Sharp, Y. Wu, G.S. Voetberg, I.N. Saab, M.E. LeNoble [1994] J Exp Bot 45: 1743-1751). The objective of the present study was to determine whether the inhibition of elongation in ABA-deficient roots is attributable to ethylene. At a psi(w) of -1.6 MPa, inhibition of root elongation in dark-grown seedlings treated with fluridone to impose ABA deficiency was largely prevented with two inhibitors of ethylene synthesis (aminooxyacetic acid and aminoethoxyvinylglycine) and one inhibitor of ethylene action (silver thiosulfate). The fluridone treatment caused an increase in the rate of ethylene evolution from intact seedlings. This effect was completely prevented with aminooxyacetic acid and also when ABA was supplied at a concentration that restored the ABA content of the root elongation zone and the root elongation rate. Consistent results were obtained when ABA deficiency was imposed using the vp5 mutant. Both fluridone-treated and vp5 roots exhibited additional morphological symptoms of excess ethylene. The results demonstrate that an important role of ABA accumulation in the maintenance of root elongation at low psi(w) is to restrict ethylene production.


Assuntos
Ácido Abscísico/metabolismo , Zea mays/metabolismo , Etilenos/biossíntese , Mutação , Raízes de Plantas/efeitos dos fármacos , Raízes de Plantas/crescimento & desenvolvimento , Raízes de Plantas/metabolismo , Piridonas/farmacologia , Água/metabolismo , Zea mays/genética , Zea mays/crescimento & desenvolvimento
9.
Eur J Biochem ; 259(1-2): 32-9, 1999 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-9914472

RESUMO

The function of high-density lipoproteins (HDLs) in reverse cholesterol transport is impaired if HDLs are subjected to oxidative stress. Polymorphonuclear neutrophils (PMNs), which have been detected in the earliest stages of atherosclerotic lesions, are one of the most likely sources of the reactive oxygen species that cause such stress. In this study, we investigated the effect of a PMN oxidative burst on HDL3. We also studied the impact on these events of pentoxifylline, a drug that regulates granulocyte function. HDL3 (370 nmol.mL-1 cholesterol-HDL) was incubated with PMNs (2 x 106. mL-1) in NaCl/Pi in the presence or absence of an iron chelate complex (10 microm Fe-nitrilotriacetic acid) at 37 degreesC for 60 min or 24 h. Phorbol myristate acetate (PMA) or formyl-methionylleucyphenylalanine (fMetLeuPhe) was used to stimulate PMNs. In iron-free NaCl/Pi medium, PMA-stimulated PMNs had a 40% lower HDL3 alpha-tocopherol content, whatever the incubation time. In NaCl/Pi medium containing iron, there was 80% less HDL3 alpha-tocopherol at 60 min, and HDL3 alpha-tocopherol had almost disappeared after 24 h. In this latter condition, the amount of thiobarbituric acid-reactive substances was significantly higher than the respective control HDL3 (P < 0.05) and oxidation of HDL3 by PMA-stimulated PMNs was associated with cross-linking of apoprotein AI, which was detected by SDS/PAGE. Similar results were obtained with fMetLeuPhe-stimulated PMN except that HDL3 alpha-tocopherol was consumed much more slowly during the first 60 min. Pretreatment of PMNs with various concentrations of pentoxifylline (0.001-20 mm) led to the concentration-dependent inhibition of oxidative modification of HDL3 induced by stimulated PMNs. The addition of 20 mm pentoxifylline in the most extreme oxidative stress conditions resulted in 70% of HDL3 alpha-tocopherol being maintained, with no formation of thiobarbituric acid-reactive substances and a lower level of apoprotein AI cross-linking. Thus HDL3 is susceptible to oxidative modifications induced by stimulated PMNs, in the presence of an exogenous source of iron. Pentoxifylline inhibited the oxidative modification of HDL3 by PMNs.


Assuntos
Lipoproteínas HDL/metabolismo , Neutrófilos/metabolismo , Pentoxifilina/farmacologia , Explosão Respiratória , Antioxidantes/metabolismo , Apolipoproteína A-I/metabolismo , Relação Dose-Resposta a Droga , Humanos , Lipoproteínas HDL3 , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Neutrófilos/efeitos dos fármacos , Oxirredução/efeitos dos fármacos , Acetato de Tetradecanoilforbol/farmacologia , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Vitamina E/metabolismo
10.
Bull Cancer ; 83(9): 773-87, 1996 Sep.
Artigo em Francês | MEDLINE | ID: mdl-8952658

RESUMO

Originally developed against the effects of ionizing radiations, amifostine is an organic thiophosphate compound shown able to selectively protect normal tissues against cytotoxic agents in cellular and animal models, without protecting tumor tissues. Amifostine is a prodrug which is dephosphorylated into its active metabolite, a free thiol derivative, by membrane alkaline phosphatase of the target issue. This unique metabolism supports its cellular selectivity and its preferential uptake by normal tissues. In phase II clinical trials, a decreased toxicity has been demonstrated in patients given alkylating agents; however, reduction of the response has not been observed. On the basis of these results, a prospective, randomized, phase III study has been conducted in patients with ovarian carcinoma receiving a combination of cisplatinum and cyclophosphamide. A significant decrease in hematologic, renal and neurologic toxicity was observed in the amifostine-treated patients compared with the control group, and response rates did not significantly differ between the two groups. Insufficient or emerging data are only available for other applications, including either in vitro manipulation of hematopoietic grafts or in vivo treatment of non-Hodgkin's lymphoma, head and neck carcinoma, non-small cell lung cancer and radioprotection. No data are yet available in regard to the potential protective effects of amifostine against mutagenicity and cancerogenicity of both chemo- and radiotherapy.


Assuntos
Amifostina/uso terapêutico , Antineoplásicos/efeitos adversos , Neoplasias/tratamento farmacológico , Protetores contra Radiação/uso terapêutico , Radioterapia/efeitos adversos , Amifostina/farmacologia , Animais , Antineoplásicos/uso terapêutico , Medula Óssea/efeitos dos fármacos , Modelos Animais de Doenças , Tolerância a Medicamentos , Células-Tronco Hematopoéticas/efeitos dos fármacos , Células-Tronco Hematopoéticas/efeitos da radiação , Humanos , Técnicas In Vitro , Rim/efeitos dos fármacos , Neoplasias Experimentais , Estudos Prospectivos , Lesões por Radiação/prevenção & controle , Protetores contra Radiação/farmacologia
11.
J Cardiovasc Pharmacol ; 25 Suppl 2: S101-5, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8699846

RESUMO

The pathogenesis of venous leg ulcers is based on the leakage of fibrinogen leading to a pericapillary fibrin cuff and plugging of capillaries by white blood cells. On the basis of a previous work, we had assumed that the key event in the pathogenesis of venous leg ulcers is related to inflammation generated by activated white blood cells that accumulate under unrelieved blood pressure, because in ulcer biopsies we had detected the presence of tumor necrosis factor-alpha (TNF-alpha) in intracapillary monocytes, elastase in the polymorphonuclear leukocytes near the vessels, and a pericapillary undegraded fibrin cuff causing a diffusion barrier to oxygen. This concept was developed because TNF-alpha synthesized by activated monocytes is responsible for many deleterious effects. It has a potent mitogenic effect on fibroblasts, leading to new collagen deposition and angiogenesis, it induces an increase in collagenase production, it acts through upregulation of an intracellular adhesion molecule (ICAM-1), leading to leukocyte sequestration and consequently a release of toxic metabolites by the polymorphonuclear cells, an early step in chronic inflammation, it activates the coagulation pathway via a marked increase in monocyte-associated tissue factor (TF) procoagulant activity, and it inhibits fibrinolysis by promoting the release of PAI-1, contributing to undegraded fibrin deposition. Therefore, we were interested in evaluating, in patients with venous leg ulcers, the effect of pentoxifylline administered at 1,200 mg daily (versus placebo) for 2-months, as this drug induces a decrease in TNF-alpha synthesis and also blocks its activity. This pilot assay was performed in blind. Evolution of several parameters in ulcer biopsies are analyzed: TNF-alpha, intact fibrin, fibrin degradation products, ICAM-1, TF, and elastase. Pentoxifylline administration induced a decrease of local elastase and of fibrin deposit. These results support the hypothesis that accumulation of activated leukocytes is the key event in venous leg ulcers.


Assuntos
Fibrina/biossíntese , Elastase Pancreática/biossíntese , Pentoxifilina/uso terapêutico , Úlcera Varicosa/tratamento farmacológico , Vasodilatadores/uso terapêutico , Anticorpos Monoclonais , Humanos , Inclusão em Parafina , Projetos Piloto , Úlcera Varicosa/metabolismo , Úlcera Varicosa/patologia
12.
J Cardiovasc Pharmacol ; 25 Suppl 2: S119-23, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8699849

RESUMO

Leukocyte adherence was studied in an original experiment that allowed study of the microcirculation in an ischemic muscle perfused by a collateral circulation. In this model, the artery feeding the cremaster muscle was ligated. Then the muscle homolateral to the ligation and its contralateral muscle were both studied by intra-vital-microscopy at 4 h, 1, 3, 7, and 21 days after the ligation. Rats were treated or not with 20 mg/kg/day pentoxifylline (PTX) i.m. In untreated rats, we found that both short-lasting and long-lasting leukocyte adherence was largely increased in the postcapillary venules of the ischemic muscle but not in its contralateral control. This dramatic increase was not limited to the hours immediately after the arterial ligation but was also found up to 3 weeks after the ligation when blood flow was almost restored to normal. This suggested that when muscle blood flow was chronically reduced, some changes promoting leukocyte adherence may occur in the endothelium. In rats treated with PTX, we found very effective inhibition of leukocyte adherence.


Assuntos
Adesão Celular/fisiologia , Circulação Colateral/fisiologia , Isquemia/patologia , Músculo Esquelético/irrigação sanguínea , Pentoxifilina/farmacologia , Vasodilatadores/farmacologia , Animais , Arteríolas/efeitos dos fármacos , Arteríolas/fisiologia , Ativação de Macrófagos/efeitos dos fármacos , Microcirculação/efeitos dos fármacos , Microcirculação/fisiologia , Músculo Esquelético/patologia , Ratos , Vênulas/efeitos dos fármacos , Vênulas/fisiologia
13.
J Cardiovasc Pharmacol ; 25 Suppl 2: S71-4, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8699866

RESUMO

Apoptosis or programmed cell death (PCD) was measured in two human cell models by flow cytometric analysis. Blood neutrophils underwent spontaneous apoptosis in short-term culture. Pentoxifylline (PTX) inhibited spontaneous neutrophil PCD. We confirmed that granulocyte/macrophage colony-stimulating factor (GM-CSF) inhibited apoptosis of polymorphonuclear neutrophils. Treatment with both GM-CSF and PTX did not increase the inhibition of PCD by either GM-CSF or PTX alone. Because apoptosis could be due to the accumulation of H2O2 in the culture medium, and because PTX has been described to reduce peroxide production, we studied the effect of adding catalase to the medium. Catalase reduced the neutrophil apoptosis and this effect was cumulative with the effect of PTX. Camptothecin, an inhibitor of topoisomerase I, induces a block in the S-phase of the cell cycle followed by apoptosis of the U937 cell line. This drug-induced apoptosis was partially inhibited by PTX, whereas the S-phase cell block was not affected. In conclusion, PTX was found to inhibit apoptosis in two different human cell types. In neutrophils, this effect appears to occur regardless of the inhibition of phosphodiesterase activity and inhibition of H2O2 release.


Assuntos
Apoptose/efeitos dos fármacos , Neutrófilos/efeitos dos fármacos , Pentoxifilina/farmacologia , Inibidores de Fosfodiesterase/farmacologia , Catalase/metabolismo , Células Cultivadas , DNA/análise , DNA/metabolismo , Eletroforese em Gel de Ágar , Citometria de Fluxo , Fator Estimulador de Colônias de Granulócitos e Macrófagos/biossíntese , Humanos , Neutrófilos/enzimologia
14.
J Cardiovasc Pharmacol ; 25 Suppl 2: S80-4, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8699868

RESUMO

The modulation of cytokine release induced by pentoxifylline (PTX) has recently been demonstrated not to be restricted solely to tumor necrosis factor (TNF)-alpha. This prompted us to study the influence of PTX on a larger spectrum of cytokines with proinflammatory actions [TNF-alpha, interleukin-6, (IL)-6, IL-1 beta, IL-8] or with implied actions in the TH1 (IL-2, IFN-gamma)/TH2 (IL-10) balance. The IL-1RA was also explored. This work was performed using a whole-blood model in which cytokine production is measured after stimulation by lipopolysaccharide (LPS) (25 micrograms/ml) and phytohemagglutinin (PHA) (5 micrograms/ml) in 1:10 diluted whole blood. The stimulation test was performed in blood from healthy controls and from septic patients (without septic shock) in the presence or absence of PTX at 10(-6), 10(-5), 10(-4), or 10(-3) M. In controls and septic patients, at a 10(-4) M PTX concentration the production of IL-2 is strongly diminished (26-32% of the basal level), followed by diminution of IFN-gamma (30-40%). As expected, of the proinflammatory cytokines TNF was the most strongly suppressed (50% of baseline) followed by IL-1 (about 80% of basal production). Finally, IL-10 was also influenced by PTX (65% of baseline). At 10(-4) M, IL-1RA and IL-6 were unaffected by PTX. Taken altogether, our data demonstrate that PTX possesses a much broader spectrum of activity on cytokine production than was initially described, and it appears to be a potential and promising immunotherapeutic agent.


Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Citocinas/biossíntese , Citocinas/fisiologia , Inflamação/metabolismo , Pentoxifilina/farmacologia , Células Th1/fisiologia , Células Th2/fisiologia , Adulto , Idoso , Sobrevivência Celular/efeitos dos fármacos , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Fito-Hemaglutininas/farmacologia , Sepse/metabolismo
15.
J Cardiovasc Pharmacol ; 25 Suppl 2: S85-7, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8699869

RESUMO

Thrombomodulin (TM) expression at the surface of endothelial cells is upregulated by cAMP analogues, whereas hypoxic conditions induce a decrease in this expression. Pentoxifylline (PTX) enhances the intracellular levels of cAMP in human umbilical vein endothelial cells (HUVECs). We therefore investigated the influence of this drug on TM expression in cells submitted to hypoxia. TM expression was quantified at the surface of HUVECs in the presence or absence of PTX during 18 h of incubation. Membrane TM was immunolabeled with a fluorescent monoclonal antibody and the expression was quantified by flow cytometric analysis. Our preliminary data revealed that PTX at 0.01 microM significantly increased TM expression levels compared with cells in hypoxia without the drug. Therefore, at this low dose PTX appears able to counterbalance the procoagulant effect of hypoxia.


Assuntos
Endotélio Vascular/metabolismo , Hipóxia/metabolismo , Pentoxifilina/farmacologia , Inibidores de Fosfodiesterase/farmacologia , Trombomodulina/metabolismo , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Células Cultivadas , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Citometria de Fluxo , Humanos
16.
J Cardiovasc Pharmacol ; 25 Suppl 2: S88-91, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8699870

RESUMO

Exposure of endothelial cells (ECs) to thrombin or cytokines leads to major changes in their biochemical properties, which confer procoagulant activities. Stimulated ECs express the procoagulant glycoprotein tissue factor (TF). Although some TF is expressed on the apical surface of the cells, most is deposited as a cryptic pool in the subendothelial matrix. This matrix-associated TF may play a role in thromboembolic complications associated with alterations in the integrity of the EC monolayer. We have measured TF activity on the surface and in the subcellular matrix of human saphenous vein ECs in culture, by assaying the TF-dependent formation of activated factor X in the presence of factor VII. The subcellular matrix was prepared by exposure of ECs to ammonium hydroxide. Incubation of ECs for 4 h with 1 U/ml human thrombin induced TF expression on the apical cell surface and in the matrix. Activity in the matrix was 4.1 +/- 0.5 times greater than on the cell surface. Pentoxifylline inhibited the expression of TF both on the cell surface and in the matrix. The EC50 was on the order of 3.9 mM in both cases. No signs of cell toxicity were observed at this concentration of pentoxifylline. Similar effects were obtained with trequinsin (HL 725), a phosphodiesterase inhibitor, with an EC50 of 40 microM. This suggests that an increase in cAMP may be involved in the mechanism of action of pentoxifylline. Inhibition of TF deposition in the matrix may be important in the prevention of thromboembolic episodes in conditions where ECs either retract or are removed by major injury.


Assuntos
AMP Cíclico/fisiologia , Endotélio Vascular/metabolismo , Isoquinolinas/farmacologia , Pentoxifilina/farmacologia , Inibidores de Fosfodiesterase/farmacologia , Inibidores da Agregação Plaquetária/farmacologia , Tetra-Hidroisoquinolinas , Tromboplastina/biossíntese , Células Cultivadas , AMP Cíclico/biossíntese , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/ultraestrutura , Humanos , Frações Subcelulares/efeitos dos fármacos , Frações Subcelulares/metabolismo
17.
J Cardiovasc Pharmacol ; 25 Suppl 2: S96-100, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8699873

RESUMO

Granulocytes play a significant role in vascular diseases. The mechanisms of neutrophil-mediated vascular injury include their increased endothelial adhesion and activation with release of inflammatory mediators. Pentoxifylline (PTX) has a well-demonstrated ability to act on the activated neutrophils. It increases chemotaxis and decreases their adherence to endothelial cells, oxidative burst, and enzyme release. In this preliminary study, we investigated the effects of PTX on ischemia-induced changes in polymorphonuclear neutrophils (PMN) activation and cytokine release. A double-blind, randomized, placebo-controlled trial was carried out in 14 patients (age range 46-86 years) suffering from critical ischemia, as defined by the European Consensus Document, or subacute ischemia due to occlusive arterial disease of the lower limb. Femoral and antecubital venous blood samples on the side of the ischemic leg were obtained from patients immediately before (TO) and after infusion (T24) of PTX or placebo. PMN activation was evaluated by study of cell migration, beta 2 integrin expression (CD11b/ CD18), oxidative burst, and elastase release. Inflammation proteins were analyzed, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), interleukin-6 (IL-6), C-reactive protein (CRP), and fibrinogen. Before treatment, our results demonstrate an important activation in both femoral and antecubital venous blood. PMN activation markers, cytokine release, and other inflammation proteins were significantly increased compared with normal subjects. In the experimental group there was no significant difference between femoral and antecubital venous blood. Six patients received PTX infusion and seven patients were in the placebo group. The effect of PTX was evaluated after 24 h of treatment (1,200 mg). In the PTX group the following variables were improved compared with the placebo group: CD11b expression on PMNs, elastase released from PMNs, fibrinogen, CRP, TNF-alpha, and IL6 in plasma. These preliminary results should be interpreted with caution because of the small sample size. Further trials may contribute to more complete understanding.


Assuntos
Arteriopatias Oclusivas/sangue , Leucócitos/metabolismo , Ativação de Macrófagos/efeitos dos fármacos , Pentoxifilina/farmacologia , Vasodilatadores/farmacologia , Idoso , Idoso de 80 Anos ou mais , Biomarcadores , Adesão Celular/efeitos dos fármacos , Quimiotaxia de Leucócito/efeitos dos fármacos , Citocinas/metabolismo , Método Duplo-Cego , Humanos , Peróxido de Hidrogênio/sangue , Integrinas/biossíntese , Perna (Membro)/irrigação sanguínea , Leucócitos/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Fluxo Sanguíneo Regional/efeitos dos fármacos
18.
Leukemia ; 5(5): 383-5, 1991 May.
Artigo em Inglês | MEDLINE | ID: mdl-1851908

RESUMO

Retinoic acid, vitamin D3, and dexamethasone are known inducers of myeloid leukemic cell differentiation. Recent evidence indicates that these drugs mediate their biological effects through binding to a nuclear receptor which belongs to the steroid/thyroid hormone receptor superfamily. This paper shows that the ligands of the other receptors of this family, estrogens, progesterone, androgens and thyroid hormone, do not induce leukemic cell differentiation. However, thyroid hormone potentiates, by one order of magnitude, the dose-response effect of retinoic acid in HL-60 cells.


Assuntos
Granulócitos/efeitos dos fármacos , Leucemia Experimental/patologia , Leucemia Mieloide/patologia , Hormônios Tireóideos/farmacologia , Tretinoína/farmacologia , Diferenciação Celular/efeitos dos fármacos , Colecalciferol/farmacologia , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Granulócitos/citologia , Humanos , Leucemia Experimental/tratamento farmacológico , Leucemia Experimental/metabolismo , Leucemia Mieloide/tratamento farmacológico , Leucemia Mieloide/metabolismo , Oxigênio/metabolismo , Estimulação Química , Tri-Iodotironina/farmacologia , Células Tumorais Cultivadas
19.
Bull Cancer ; 76(6): 637-42, 1989.
Artigo em Francês | MEDLINE | ID: mdl-2775883

RESUMO

One hundred two patients submitted to intensive chemotherapy were included in a randomized study with cross over comparing for the second course two anti-emetics: tetracosactide (D1: 3 mg, D2 and D3: 2 mg/d) and methylprednisolone (D1: 240 mg, D2 and D3: 160 mg/d). Most patients presented with malignant lymphoma. All patients experienced nausea and emesis during first course of chemotherapy. Results were similar in both groups, respectively for tetracosactide and methylprednisolone: no nausea 37 versus 40%, less than 3 emesis 69% versus 73%. Secondary effects were observed in 5 and 8% of cases. Tetracosactide with a schedule of 7 mg for 3 days gives the same results than methylprednisolone 560 mg for 3 days in chemotherapy induced nausea and emesis prevention.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Cosintropina/uso terapêutico , Metilprednisolona/uso terapêutico , Náusea/tratamento farmacológico , Vômito/tratamento farmacológico , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Distribuição Aleatória , Vômito/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA